Merus Nv (MRUS)

$50

-0.37

(-0.73%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $48.24
    $50.36
    $50.00
    downward going graph

    3.52%

    Downside

    Day's Volatility :4.21%

    Upside

    0.71%

    downward going graph
  • $19.81
    $61.61
    $50.00
    downward going graph

    60.39%

    Downside

    52 Weeks Volatility :67.85%

    Upside

    18.84%

    downward going graph

Returns

PeriodMerus NvSector (Health Care)Index (Russel 2000)
3 Months
-5.48%
5.1%
0.0%
6 Months
6.13%
4.9%
0.0%
1 Year
110.35%
16.6%
0.0%
3 Years
89.9%
13.2%
-22.3%

Highlights

Market Capitalization
3.4B
Book Value
$11.01
Earnings Per Share (EPS)
-2.89
PEG Ratio
0.0
Wall Street Target Price
87.62
Profit Margin
0.0%
Operating Margin TTM
-877.99%
Return On Assets TTM
-19.62%
Return On Equity TTM
-33.39%
Revenue TTM
35.2M
Revenue Per Share TTM
0.61
Quarterly Revenue Growth YOY
-30.0%
Gross Profit TTM
-107.8M
EBITDA
-194.6M
Diluted Eps TTM
-2.89
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.1
EPS Estimate Next Year
-3.63
EPS Estimate Current Quarter
-0.77
EPS Estimate Next Quarter
-0.76

Analyst Recommendation

Buy
    95%Buy
    5%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Merus Nv(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
19
18
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 75.24%

Current $50.00
Target $87.62

Company Financials

FY18Y/Y Change
Revenue
36.0M
↑ 141.72%
Net Income
-27.8M
↓ 68.34%
Net Profit Margin
-77.17%
↑ 512.02%
FY19Y/Y Change
Revenue
31.1M
↓ 13.46%
Net Income
-55.2M
↑ 98.66%
Net Profit Margin
-177.15%
↓ 99.98%
FY20Y/Y Change
Revenue
29.9M
↓ 3.82%
Net Income
-85.5M
↑ 55.05%
Net Profit Margin
-285.59%
↓ 108.44%
FY21Y/Y Change
Revenue
49.1M
↑ 64.0%
Net Income
-66.8M
↓ 21.86%
Net Profit Margin
-136.06%
↑ 149.53%
FY22Y/Y Change
Revenue
41.6M
↓ 15.32%
Net Income
-131.2M
↑ 96.35%
Net Profit Margin
-315.48%
↓ 179.42%
FY23Y/Y Change
Revenue
43.9M
↑ 5.68%
Net Income
-154.9M
↑ 18.1%
Net Profit Margin
-352.56%
↓ 37.08%
Q1 FY23Q/Q Change
Revenue
13.5M
↑ 26.56%
Net Income
-39.7M
↓ 51.52%
Net Profit Margin
-294.4%
↑ 474.14%
Q2 FY23Q/Q Change
Revenue
10.5M
↓ 22.39%
Net Income
-32.0M
↓ 19.4%
Net Profit Margin
-305.78%
↓ 11.38%
Q3 FY23Q/Q Change
Revenue
11.0M
↑ 5.32%
Net Income
-23.0M
↓ 28.16%
Net Profit Margin
-208.57%
↑ 97.21%
Q4 FY23Q/Q Change
Revenue
8.9M
↓ 18.98%
Net Income
-60.2M
↑ 161.4%
Net Profit Margin
-672.93%
↓ 464.36%
Q1 FY24Q/Q Change
Revenue
7.9M
↓ 11.75%
Net Income
-34.5M
↓ 42.72%
Net Profit Margin
-436.76%
↑ 236.17%
Q2 FY24Q/Q Change
Revenue
7.3M
↓ 7.06%
Net Income
-50.0M
↑ 45.23%
Net Profit Margin
-682.52%
↓ 245.76%
FY18Y/Y Change
Total Assets
250.0M
↑ 5.87%
Total Liabilities
144.9M
↓ 18.91%
FY19Y/Y Change
Total Assets
263.4M
↑ 5.37%
Total Liabilities
132.1M
↓ 8.83%
FY20Y/Y Change
Total Assets
231.2M
↓ 12.21%
Total Liabilities
129.0M
↓ 2.36%
FY21Y/Y Change
Total Assets
456.6M
↑ 97.48%
Total Liabilities
140.4M
↑ 8.88%
FY22Y/Y Change
Total Assets
376.5M
↓ 17.53%
Total Liabilities
129.5M
↓ 7.77%
FY23Y/Y Change
Total Assets
458.5M
↑ 21.76%
Total Liabilities
102.2M
↓ 21.11%
Q1 FY23Q/Q Change
Total Assets
338.5M
↓ 10.1%
Total Liabilities
121.0M
↓ 6.56%
Q2 FY23Q/Q Change
Total Assets
363.6M
↑ 7.42%
Total Liabilities
106.2M
↓ 12.21%
Q3 FY23Q/Q Change
Total Assets
492.2M
↑ 35.36%
Total Liabilities
98.8M
↓ 6.99%
Q4 FY23Q/Q Change
Total Assets
458.5M
↓ 6.85%
Total Liabilities
102.2M
↑ 3.39%
Q1 FY24Q/Q Change
Total Assets
498.1M
↑ 8.63%
Total Liabilities
148.6M
↑ 45.51%
Q2 FY24Q/Q Change
Total Assets
892.2M
↑ 79.13%
Total Liabilities
145.5M
↓ 2.14%
FY18Y/Y Change
Operating Cash Flow
-46.3M
↑ 3.21%
Investing Cash Flow
-25.2M
↓ 39.54%
Financing Cash Flow
59.0M
↓ 73.59%
FY19Y/Y Change
Operating Cash Flow
-63.0M
↑ 36.09%
Investing Cash Flow
24.2M
↓ 196.05%
Financing Cash Flow
74.2M
↑ 25.79%
FY20Y/Y Change
Operating Cash Flow
-79.9M
↑ 26.73%
Investing Cash Flow
-1.5M
↓ 106.15%
Financing Cash Flow
39.5M
↓ 46.76%
FY21Y/Y Change
Operating Cash Flow
-59.6M
↓ 25.37%
Investing Cash Flow
-146.6M
↑ 9766.96%
Financing Cash Flow
282.0M
↑ 613.45%
FY22Y/Y Change
Operating Cash Flow
-149.9M
↑ 151.39%
Investing Cash Flow
2.8M
↓ 101.91%
Financing Cash Flow
58.7M
↓ 79.17%
Q1 FY23Q/Q Change
Operating Cash Flow
-36.7M
↑ 20.42%
Investing Cash Flow
-24.5M
↓ 2964.25%
Financing Cash Flow
217.0K
↓ 200.93%
Q2 FY23Q/Q Change
Operating Cash Flow
-41.6M
↑ 13.18%
Investing Cash Flow
-24.5M
↑ 0.0%
Financing Cash Flow
66.0M
↑ 30299.54%

Technicals Summary

Sell

Neutral

Buy

Merus Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Merus Nv
Merus Nv
2.04%
6.13%
110.35%
89.9%
203.03%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Merus Nv
Merus Nv
NA
NA
0.0
-3.1
-0.33
-0.2
NA
11.01
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Merus Nv
Merus Nv
Buy
$3.4B
203.03%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Merus Nv

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 11.03M → 7.33M (in $), with an average decrease of 12.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -34.45M → -50.04M (in $), with an average decrease of 45.2% per quarter

Institutional Holdings

  • FMR Inc

    9.13%

  • RTW INVESTMENTS, LLC

    6.11%

  • COMMODORE CAPITAL LP

    4.69%

  • Deerfield Management Co

    4.03%

  • Federated Hermes Inc

    3.52%

  • Samlyn Capital, LLC

    3.41%

Corporate Announcements

  • Merus Nv Earnings

    Merus Nv’s price-to-earnings ratio stands at None

    Read More

Company Information

merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

Organization
Merus Nv
Employees
172
CEO
Dr. Sven Ante Lundberg M.D.
Industry
Health Technology

Discover More

FAQs